Chemotherapy is central to the treatment of advanced or metastatic urothelial carcinoma (UC), and platinum-based treatments, like cisplatin, have been the first-line treatment options for many years. To address the limitations of platinum-based chemotherapeutics, additional therapeutics have become available in more recent years for first- and second-line use. Specifically, for patients who are cisplatin-ineligible or those who relapse, immune checkpoint inhibitors, such as avelumab, pembrolizumab, and atezolizumab, targeting the program cell death 1 protein (PD-1) or its ligand (PD-L1), have gained FDA approval. Latest clinical trials have also combined immunotherapy drugs with novel therapies, like the antibody-drug conjugate enfortumab vedotin, to demonstrate high response rates; this has instigated further studies into comparison with platinum-based chemotherapeutics. Evidence of disruption to the fibroblast growth factor receptor (FGFR) signaling pathway in UC has also resulted in multiple studies investigating FGFR inhibitors, like rogaratinib, as a potential treatment option for patients with UC.

In this deep dive, American Society of Clinical Oncology (ASCO) 2021 presenters Petros Grivas, MD, PhD, University of Washington School of Medicine & Fred Hutchinson Cancer Research Center, Seattle, WA; Terence W. Friedlander, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; and Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, will be sharing their insights into the latest advancements in immunotherapy for advanced urothelial carcinoma. Our experts will present the latest data from the JAVELIN Bladder 100, EV-103, and FORT-2 trials.

This year, at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021, experts came together virtually to present and discuss the latest findings in oncology.

In this podcast, Pedro Barata, MD, MSc Tulane University School of Medicine, New Orleans, LA, discusses highlights from the meeting. He focuses on the results from four Phase III trials assessing various therapies for the treatment of prostate cancer. Dr Barata begins with VISION (NCT03511664), examining the addition of lutetium-177 to standard of care treatment in progressive metastatic prostate cancer, followed by PEACE-1 (NCT01957436), investigating abiraterone and prednisone ± radiotherapy for hormone-naïve metastatic patients. He continues by highlighting Peace III (NCT02194842), a trial investigating enzalutamide and radium-223 combination therapy in asymptomatic or mildly symptomatic castration-resistance patients and concludes by talking about the SWOG S1216 study (NCT01809691), examining androgen deprivation therapy plus TAK-700 in patients with hormone-sensitive prostate cancer.

This interview took place at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021.

VJOncology has assembled an international panel of leading breast cancer experts to discuss the latest advances and data from the virtual American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

In this podcast, Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Giuseppe Curigliano, MD, University of Milan, Milan, Italy, Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Andrew Tutt, MBChB, PhD, The Institute of Cancer Research, London, UK, to examine the recent major breakthroughs in breast cancer and what they mean for clinical practice.

Tune in to hear the expert panel offer their perspectives on adjuvant olaparib and the results of the OlympiA trial, capecitabine in the ECOG study, the GeparNuevo trial which looked at adding durvalumab to chemotherapy in patients with TNBC, as well as first-line paclitaxel plus durvalumab for TNBC in the BEGONIA trial. The panel also discuss the latest data for CDK4/6 inhibitors, SERDs and BCL-2 inhibitors, the use of talazoparib in the neoadjuvant setting and much more.

The post The Breast Cancer Sessions: Highlights from ASCO 2021 appeared first on VJOncology.

During the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, an exciting array of advances in genitourinary (GU) cancer research were presented. VJOncology has brought together a panel of leading GU experts to consider and debate the latest developments in bladder and kidney cancer and offer their perspectives on how they could impact patient care in the future.

This post-ASCO GU cancer roundtable discussion is chaired by Elizabeth Plimack, MD, MS, from the Fox Chase Cancer Center, Philadelphia, PA, who is joined by  Rana McKay, MD, University of California San Diego, San Diego, CA, and Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK.

Listen to this podcast to learn about the latest research in immunotherapy for the treatment of muscle-invasive bladder cancer and the exciting recent developments in bladder-sparing approaches. The panel also discuss groundbreaking adjuvant pembrolizumab data from KEYNOTE-564 in renal cell carcinoma (RCC) and how it will change their clinical practice in the future. In addition, we hear about updated results from the CLEAR trial, KEYNOTE-426, as well as alternative approaches in treating advanced RCC such as using the probiotic CBM588 in conjunction with immunotherapy.

The post The GU Cancer Sessions: Bladder and Kidney Highlights from ASCO 2021 appeared first on VJOncology.

During the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, an exciting array of advances in genitourinary (GU) cancer research were presented. VJOncology has brought together a panel of leading GU experts to consider and debate the latest developments in bladder and kidney cancer and offer their perspectives on how they could impact patient care in the future.  

This post-ASCO GU cancer roundtable discussion is chaired by Elizabeth Plimack, MD, MS, from the Fox Chase Cancer Center, Philadelphia, PA, who is joined by  Rana McKay, MD, University of California San Diego, San Diego, CA, and Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK.         

Listen to this podcast to learn about the latest research in immunotherapy for the treatment of muscle-invasive bladder cancer and the exciting recent developments in bladder-sparing approaches. The panel also discuss ground-breaking adjuvant pembrolizumab data from KEYNOTE-564 in renal cell carcinoma (RCC) and how it will change their clinical practice in the future. In addition, we hear about updated results from the CLEAR trial, KEYNOTE-426, as well as alternative approaches in treating advanced RCC such as using the probiotic CBM588 in conjunction with immunotherapy.

VJOncology has assembled an international panel of leading breast cancer experts to discuss the latest advances and data from the virtual American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

In this podcast, Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Giuseppe Curigliano, MD, University of Milan, Milan, Italy, Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Andrew Tutt, MBChB, PhD, The Institute of Cancer Research, London, UK, to examine the recent major breakthroughs in breast cancer and what they mean for clinical practice.

Tune in to hear the expert panel offer their perspectives on adjuvant olaparib and the results of the OlympiA trial, capecitabine in the ECOG study, the GeparNuevo trial which looked at adding durvalumab to chemotherapy in patients with TNBC, as well as first-line paclitaxel plus durvalumab for TNBC in the BEGONIA trial. The panel also discuss the latest data for CDK4/6 inhibitors, SERDs and BCL-2 inhibitors, the use of talazoparib in the neoadjuvant setting and much more.